Search

Your search keyword '"Goodman, S G"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Goodman, S G" Remove constraint Author: "Goodman, S G"
89 results on '"Goodman, S G"'

Search Results

1. Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES

3. Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome

4. Initial Invasive or Conservative Strategy for Stable Coronary Disease

7. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome

14. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

15. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

17. P1932Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study

18. 4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

19. 4348Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine

20. Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? : Insights from the APPRAISE-2 trial

25. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis

26. Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial

28. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE).

29. Prognostic value of dipyridamole SPECT imaging in low-risk patients after myocardial infarction.

33. Empagliflozin after Acute Myocardial Infarction.

34. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia.

37. Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial

38. Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial).

39. Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial

40. Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries.

41. Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial

42. Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification.

43. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.

44. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network.

45. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy.

46. Low-molecular-weight heparin in patients with non-ST-segment elevation acute coronary syndrome: role in the emergency department.

47. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.

48. Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate.

49. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.

50. ECG subanalyses in clinical trials: an investigator's perspective.

Catalog

Books, media, physical & digital resources